Stochter
Profile Picture
The Investor 19 Nov 2026, 18:48
Alnylam Wins $25 Million Milestone as Regeneron’s Livsayis Secures FDA Approval

Alnylam Pharmaceuticals (NASDAQ: ALNY) said Regeneron received FDA approval for Livsayis (cemdisiran) to treat adults with anti-AChR antibody-positive generalized myasthenia gravis, marking the first RNAi therapy approved for the disease.

Livsayis was discovered by Alnylam and later transferred to Regeneron under the companies’ RNAi collaboration. Regeneron now holds responsibility for development, manufacturing and commercialization of the therapy.

Under the collaboration agreement, Alnylam will receive a $25 million payment triggered by the FDA approval and is eligible for tiered double-digit royalties of up to 15% on global net sales of Livsayis.

The approval strengthens the economics of Alnylam’s partnered pipeline while further validating its RNAi platform. Livsayis is the seventh Alnylam-discovered RNAi therapy to receive FDA approval in less than nine years, adding a new royalty-bearing product without requiring Alnylam to fund commercialization.

Comments

No comments yet.

Ana sayfa